Officer Dennis Mulroy Files to Sell Additional $1.15M in Stock, Continuing Recent Trend
ANAB has more than doubled off its 52-week low of $11.402.
Summary
AnaptysBio officer Dennis Mulroy has filed to sell an additional $1.15 million in company stock, extending a recent pattern of significant insider sales totaling over $17 million in the last three months.
Key Events · Ownership and Investor Activity · ANAB
-
Officer Files Intent to Sell
Dennis Mulroy, an officer at AnaptysBio, has filed a Form 144 indicating intent to sell 20,000 shares of common stock, with an approximate market value of $1.15 million.
-
Continuation of Sales Pattern
This filing extends a recent trend of significant sales by Mr. Mulroy, who has sold a total of 297,900 shares for gross proceeds of over $16.1 million in the past three months, bringing his total sales (including this filing) to over $17.2 million.
-
Shares Acquired via Option Exercise
The shares intended for sale were acquired through a stock option exercise, a common method for officers to monetize compensation.
-
Context of Share Repurchase Program
These ongoing officer sales occur while the company has an active $100 million share repurchase program, announced in May 2026, which could be seen as conflicting signals regarding management's view on valuation.
Analysis · ANAB · Life Sciences
This Form 144 indicates an officer's intent to sell a substantial amount of company stock, adding to a pattern of significant insider sales. While the shares are acquired through option exercises, the continuous disposition of over $17 million in stock by a single officer over three months, especially when the company has a share repurchase program, can be interpreted negatively by investors. It suggests a lack of conviction in the stock's near-term appreciation from a key insider.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $56.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.